StockWatch
·

KANORIA CHEMICALS & INDUSTRIES LTD. Q2 FY27 Results

KANORICHEMQ2 FY27 Results
Filing
Result:Good· Market: Up#Turnaround#Margin expansion
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue357.9822.2%70.6%
Total Income360.7622.8%62.4%
Expenditure330.1923.6%49.4%
PBT30.5713.3%2558.3%
Net Profit22.7213.8%75.3%
OPM12.10%2.32pp9.13pp
NPM6.30%0.66pp35.03pp
EPS5.2013.8%3614.3%
View full financials

Chemicals/manufacturing lens on adjusted continuing-operations profit shows a genuine turnaround (from a ₹2.24 Cr loss to ₹22.72 Cr profit) with 70.6% revenue growth and EBITDA margin expanding from ~8.8% to ~12.9%, while the headline 75% PAT decline is purely a prior-year one-off distortion, not a sign of weaker performance.

Q2 FY-2027 RESULTS · KANORICHEM

Kanoria Chemicals: consolidated PAT ₹22.7 Cr as core business turns profitable YoY

PAT -75.25% YoY · revenue +70.6% · margins expanding

13 Nov 2026 · 3 min read
Revenue

₹357.98 Cr

+70.6% YoY

PAT (consolidated)

₹22.72 Cr

-75.25% YoY

Net margin

6.3%

-35pp YoY

EPS

₹5.2

Kanoria Chemicals' consolidated PAT was ₹22.72 Cr for Q2 FY27 (quarter ended 30 September 2026), on revenue from operations of ₹357.98 Cr, up 70.6% YoY from ₹209.84 Cr. Reported consolidated PAT looks like a 75.3% YoY decline against last year's ₹91.81 Cr, but that figure is inflated by a ₹97.66 Cr one-off gain on loss of control of a discontinued subsidiary booked in Q2 FY26; stripping it out, continuing operations swung from a ₹2.24 Cr loss a year ago to this quarter's ₹22.72 Cr profit — the core-business turnaround the company itself highlighted in its results disclosure. Standalone PAT, which was never affected by that subsidiary, confirms the cleaner read: it grew 258% YoY to ₹23.27 Cr from ₹6.50 Cr, diverging sharply from the consolidated headline purely because of last year's one-off, not weaker underlying performance. Sequentially, revenue eased 22.2% from Q1 FY27's ₹460.37 Cr and PAT was down 13.8% from ₹26.36 Cr — a pull-back after a strong first quarter rather than a change in trend.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹357.98 Cr-22.2%+70.6%
Expenses₹330.19 Cr-23.5%+49.4%
PAT₹22.72 Cr-13.81%-75.25%
Net margin6.3%+0.7pp-35pp
EPS₹5.2-13.8%+3614.3%

EBITDA margin improved to roughly 12.9% of revenue this quarter from about 8.8% a year ago on a continuing-operations basis, while net margin moved from a negative base to roughly 6.3%, consistent with the swing to profit; sequentially, margins held broadly steady versus Q1 FY27 (reported OPM 9.78%, NPM 5.64%). There is no prior management guidance or outlook on record for this company, and no formal analyst/street estimate for Q2 FY27 could be located in public sources, so the print cannot be benchmarked against either; management's press release accompanying this filing was also not available for review. On the corporate side, the same board meeting approved re-appointing Rajya Vardhan Kanoria as Managing Director for a further three years from 10 January 2027, and the quarter follows the October 2026 commissioning of a new 12 TPD Triacetin facility — a plausible, though filing-unconfirmed, contributor to the YoY revenue growth. The sole subsidiary, Kanoria Africa Textiles (Ethiopia), remains small: ₹30.71 Cr of pre-consolidation quarterly revenue and a ₹0.55 Cr loss, so standalone and consolidated PAT (₹23.27 Cr vs ₹22.72 Cr) stay close this quarter.

₹
143.15159.59176.03192.47208.91180.2808-1009-0109-2410-1911-1111-13Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹180.28, down 0.5% over the past month of trading.

₹ Cr
-26.4517.1960.84104.48-13.78Q1 FY26rev ₹454 Cr91.81Q2 FY26rev ₹210 Cr3.55Q3 FY26rev ₹266 Cr31.62Q4 FY26rev ₹304 Cr26.36Q1 FY27rev ₹460 Cr22.72Q2 FY27rev ₹358 Cr
Quarterly consolidated PAT, ₹ Crore
Beyond the headline

What the summary numbers don't show

EPS ₹5.20 (continuing & discontinued combined) vs ₹(0.51) YoY (continuing ops) and ₹6.03 in Q1 FY27

  • W1

    Whether revenue holds above Q2's ₹357.98 Cr run-rate after the October 2026 12 TPD Triacetin facility ramp-up, given the 22.2% QoQ dip from Q1 FY27's ₹460.37 Cr

  • W2

    Continuing-operations EBITDA margin trajectory — whether it sustains near this quarter's ~12.9% after two straight quarters of recovery from ~8.8% a year ago

  • W3

    Impact of the ₹49.50 Cr 7% NCRPS issued in April 2026 on future finance costs/dividends as H1 saw ₹49.57 Cr of long-term borrowings repaid

Figures converted from INR Lakhs (÷100). totalExpenses includes finance costs + D&A so it reconciles to PBT. Consolidated Q2 FY26 base includes a ₹97.66 Cr one-off gain on loss of control of a discontinued subsidiary, which inflates the YoY PAT decline; standalone had no such item and no discontinued-operations line this period (nil exceptional item vs ₹10.64 Cr APAG impairment in the year-ago/FY26 base).

Informational and educational content only. Not investment advice.